[go: up one dir, main page]

PE20190171A1 - Anticuerpos de union a trombina y usos del mismo - Google Patents

Anticuerpos de union a trombina y usos del mismo

Info

Publication number
PE20190171A1
PE20190171A1 PE2018002007A PE2018002007A PE20190171A1 PE 20190171 A1 PE20190171 A1 PE 20190171A1 PE 2018002007 A PE2018002007 A PE 2018002007A PE 2018002007 A PE2018002007 A PE 2018002007A PE 20190171 A1 PE20190171 A1 PE 20190171A1
Authority
PE
Peru
Prior art keywords
trombina
union
antibodies
same
epitope
Prior art date
Application number
PE2018002007A
Other languages
English (en)
Inventor
James Andrew Huntington
Trevor Baglin
Jonathan Langdown
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of PE20190171A1 publication Critical patent/PE20190171A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a una molecula aislada de anticuerpo que se une especificamente a un epitope del exosito 1 de la trombina humana madura los cuales reconocen el epitope del exosito 1 de la trombina e inhiben selectivamente la trombina sin promover el sangrado. Estas moleculas de anticuerpos pueden ser utiles en el tratamiento y prevencion de la trombosis, embolismo, entre otros. Tambien se refiere a una composicion farmaceutica y un metodo de tratamiento.
PE2018002007A 2011-12-14 2012-12-14 Anticuerpos de union a trombina y usos del mismo PE20190171A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1121513.4A GB201121513D0 (en) 2011-12-14 2011-12-14 Thrombin-binding antibody molecules and uses thereof
PCT/GB2012/053140 WO2013088164A1 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof

Publications (1)

Publication Number Publication Date
PE20190171A1 true PE20190171A1 (es) 2019-02-01

Family

ID=45560465

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014000953A PE20141706A1 (es) 2011-12-14 2012-12-14 Anticuerpos de union a trombina y usos del mismo
PE2018002007A PE20190171A1 (es) 2011-12-14 2012-12-14 Anticuerpos de union a trombina y usos del mismo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2014000953A PE20141706A1 (es) 2011-12-14 2012-12-14 Anticuerpos de union a trombina y usos del mismo

Country Status (34)

Country Link
US (5) US9518129B2 (es)
EP (2) EP3275903A1 (es)
JP (2) JP6216954B2 (es)
KR (1) KR102114506B1 (es)
CN (2) CN107936119B (es)
AU (2) AU2012351858B2 (es)
BR (1) BR112014014605A2 (es)
CA (1) CA2856656C (es)
CO (1) CO7101192A2 (es)
CY (1) CY1119599T1 (es)
DK (1) DK2791177T3 (es)
ES (1) ES2642718T3 (es)
GB (1) GB201121513D0 (es)
HK (1) HK1246326A1 (es)
HR (1) HRP20171775T1 (es)
HU (1) HUE034793T2 (es)
IL (1) IL232797B (es)
LT (1) LT2791177T (es)
ME (1) ME02901B (es)
MX (2) MX376876B (es)
MY (1) MY170980A (es)
NO (1) NO2791177T3 (es)
PE (2) PE20141706A1 (es)
PH (1) PH12014501169A1 (es)
PL (1) PL2791177T3 (es)
PT (1) PT2791177T (es)
RS (1) RS56510B1 (es)
RU (2) RU2642276C2 (es)
SG (1) SG11201402560WA (es)
SI (1) SI2791177T1 (es)
SM (1) SMT201700580T1 (es)
UA (1) UA116531C2 (es)
WO (1) WO2013088164A1 (es)
ZA (1) ZA201403836B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) * 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201310949D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Binding Motif
GB201310948D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Screening methods
MX2018009264A (es) * 2016-02-05 2018-08-28 Jiangsu Hengrui Medicine Co Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
CN107043423B (zh) * 2016-02-05 2021-02-26 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途
WO2018081534A1 (en) * 2016-10-28 2018-05-03 President And Fellows Of Harvard College Assay for exo-site binding molecules
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
WO2020003077A1 (en) * 2018-06-25 2020-01-02 Janssen Pharmaceutica Nv Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0417193B1 (en) * 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
CA2082643A1 (en) 1990-05-10 1991-11-11 Jan H. Nuijens Inhibitors of factor xii activation and applications thereof
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5443827A (en) * 1993-05-03 1995-08-22 President And Fellows Of Harvard College Fibrin-targeted inhibitors of thrombin
CA2180140A1 (en) * 1993-12-27 1995-07-06 Jeffrey I. Weitz Methods and compositions for inhibiting thrombogenesis
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
WO2001000667A2 (en) 1999-06-29 2001-01-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-thrombin peptide from anopheles albimanus salivary gland
CA2378473A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation of platelet activation
CN100339132C (zh) * 2000-05-15 2007-09-26 史密丝克莱恩比彻姆公司 抗血栓剂
WO2002017711A2 (en) 2000-08-31 2002-03-07 Cor Therapeutics, Inc. Therapeutics and diagnostics based on a novel signal transduction system in platelets
CA2453202C (en) * 2001-07-06 2012-10-16 Oregon Health & Science University Peptides which modulate blood coagulation and methods of use thereof
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
MEP0208A (xx) 2005-08-26 2010-02-10 Archemix Corp Aptameri koji vezuje trombin sa visokim afininitetom
JP2009530312A (ja) 2006-03-15 2009-08-27 エモリー ユニヴァーシティ トロンビン阻害剤の抗凝固効果を阻害するためのトロンビン変異体の使用
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
PL2297207T3 (pl) 2008-06-19 2019-03-29 Prothix Bv Zastosowanie przeciwciał przeciw czynnikowi XI do zapobiegania lub leczenia tworzenia skrzepliny
US20110275701A1 (en) 2008-09-18 2011-11-10 Archemix Corp. Anti-thrombin aptamer formulations and methods for use
LT2734552T (lt) 2011-07-22 2025-01-10 Csl Behring Gmbh Inhibitoriniai monokloniniai antikūnai prieš xii/xiia faktorių ir jų panaudojimas
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof

Also Published As

Publication number Publication date
SI2791177T1 (en) 2018-03-30
LT2791177T (lt) 2017-11-27
UA116531C2 (uk) 2018-04-10
PT2791177T (pt) 2017-11-29
US20210371543A1 (en) 2021-12-02
CY1119599T1 (el) 2018-04-04
MY170980A (en) 2019-09-23
US10287363B2 (en) 2019-05-14
RU2017144629A3 (es) 2021-04-05
US9988463B2 (en) 2018-06-05
RU2642276C2 (ru) 2018-01-24
EP3275903A1 (en) 2018-01-31
US20190276558A1 (en) 2019-09-12
AU2017268655B2 (en) 2019-05-09
SMT201700580T1 (it) 2018-01-11
JP2015501830A (ja) 2015-01-19
CA2856656C (en) 2021-01-19
RS56510B1 (sr) 2018-02-28
EP2791177B1 (en) 2017-09-06
US20170066842A1 (en) 2017-03-09
PH12014501169B1 (en) 2014-09-08
HK1202564A1 (en) 2015-10-02
IL232797B (en) 2018-07-31
CO7101192A2 (es) 2014-10-31
JP6216954B2 (ja) 2017-10-25
WO2013088164A1 (en) 2013-06-20
US9518129B2 (en) 2016-12-13
RU2017144629A (ru) 2019-02-18
ES2642718T3 (es) 2017-11-17
NO2791177T3 (es) 2018-02-03
PH12014501169A1 (en) 2014-09-08
AU2012351858B2 (en) 2017-10-05
RU2014124985A (ru) 2016-02-10
IL232797A0 (en) 2014-07-31
ME02901B (me) 2018-04-20
EP2791177A1 (en) 2014-10-22
AU2017268655A1 (en) 2017-12-21
KR102114506B1 (ko) 2020-05-22
MX2014007170A (es) 2015-04-17
SG11201402560WA (en) 2014-06-27
KR20140105556A (ko) 2014-09-01
PL2791177T3 (pl) 2018-03-30
JP2018039798A (ja) 2018-03-15
HRP20171775T1 (hr) 2017-12-29
HK1246326A1 (en) 2018-09-07
US20140370008A1 (en) 2014-12-18
HUE034793T2 (en) 2018-02-28
JP6705785B2 (ja) 2020-06-03
MX353281B (es) 2018-01-08
CN104053673B (zh) 2018-01-12
AU2012351858A1 (en) 2014-06-12
MX376876B (es) 2025-03-07
CN104053673A (zh) 2014-09-17
CN107936119A (zh) 2018-04-20
CN107936119B (zh) 2021-06-15
GB201121513D0 (en) 2012-01-25
BR112014014605A2 (pt) 2017-06-13
ZA201403836B (en) 2015-12-23
NZ625386A (en) 2017-03-31
PE20141706A1 (es) 2014-11-13
US20180334511A1 (en) 2018-11-22
DK2791177T3 (en) 2017-12-18
CA2856656A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
PE20190171A1 (es) Anticuerpos de union a trombina y usos del mismo
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
EA201791093A1 (ru) Антитела к cd47, способы и применение
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
EA201791485A1 (ru) Анти-cd47-антитела и их применения
PE20161390A1 (es) Anticuerpos multiespecificos
PE20250415A1 (es) Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PE20150159A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p
PE20142168A1 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
EA201690159A1 (ru) Способы и композиции для лечения рака
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
EA201690992A1 (ru) Антитела, специфичные к fcrn
EA202091557A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
DOP2018000019A (es) Inmunoconjugados de il22